2023
Early Flexible Sigmoidoscopy Improves Clinical Outcomes in Acute Severe Ulcerative Colitis
Sharma S, Li D, Levine L, Chaar A, McMillan C, Gaidos J, Proctor D, Al-Bawardy B. Early Flexible Sigmoidoscopy Improves Clinical Outcomes in Acute Severe Ulcerative Colitis. Crohn's & Colitis 360 2023, 5: otad032. PMID: 37323477, PMCID: PMC10263117, DOI: 10.1093/crocol/otad032.Peer-Reviewed Original ResearchAcute severe ulcerative colitisSevere ulcerative colitisClinical outcomesSigmoidoscopy groupHospital stayFlexible sigmoidoscopyUlcerative colitisIntravenous corticosteroid useRate of colectomyRisk of colectomyHours of admissionOpioid medication useShorter hospital stayCohort of patientsFavorable clinical outcomeLarge prospective studiesRelevant clinical outcomesColectomy rateCorticosteroid useSecondary outcomesMedication usePrimary outcomeProspective studyRetrospective studySigmoidoscopy
2022
IMPACT OF THIOPURINE DOSE IN COMBINATION THERAPY IN INFLAMMATORY BOWEL DISEASE
Nawaz A, Glick L, Li D, Gaidos J, Proctor D, Al-Bawardy B. IMPACT OF THIOPURINE DOSE IN COMBINATION THERAPY IN INFLAMMATORY BOWEL DISEASE. Inflammatory Bowel Diseases 2022, 28: s107-s108. DOI: 10.1093/ibd/izac015.174.Peer-Reviewed Original ResearchSteroid-free clinical remissionC-reactive proteinNon-therapeutic dosesInflammatory bowel diseaseNormal C-reactive proteinAnti-TNF antibodiesCombination therapyTherapeutic doseEndoscopic healingNTD groupAntibody formationUlcerative colitisClinical outcomesCrohn's diseaseNormal serum C-reactive proteinAnti-TNF combination therapyAnti-TNF drug levelsSerum C-reactive proteinEffect of thiopurinesImpact of thiopurinesAnti-TNF treatmentRetrospective cohort studyNormal TPMT activityUnpaired Student's t-testTerms of baselineImpact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease
Nawaz A, Glick L, Chaar A, Li D, Gaidos J, Proctor D, Al-Bawardy B. Impact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease. Annals Of Gastroenterology 2022, 36: 39-44. PMID: 36593807, PMCID: PMC9756033, DOI: 10.20524/aog.2022.0766.Peer-Reviewed Original ResearchInflammatory bowel diseaseC-reactive proteinAnti-TNF combination therapySteroid-free clinical remissionCombination therapyThiopurine doseDose groupEndoscopic healingClinical remissionBowel diseaseUlcerative colitisCrohn's diseaseTherapeutic doseNormal serum C-reactive proteinAnti-tumor necrosis factorNormal C-reactive proteinSerum C-reactive proteinAnti-drug antibody formationAnti-TNF immunogenicityCohort of patientsLow-dose groupSignificant differencesSecondary outcomesPrimary outcomeClinical outcomes
2020
The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study
Ramos GP, Dimopoulos C, McDonald NM, Janssens LP, Hung KW, Proctor D, Ruggiero E, Kane S, Bruining DH, Faubion WA, Raffals LE, Loftus EV, Al-Bawardy B. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. Inflammatory Bowel Diseases 2020, 27: 1270-1276. PMID: 33165569, DOI: 10.1093/ibd/izaa293.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseExtraintestinal manifestationsPeripheral arthritisBowel diseaseDose of vedolizumabPrevious biologic useMulticenter retrospective studyCurrent medical therapyTerms of ageConcurrent immunosuppressantsCorticosteroid therapyVDZ treatmentIBD subtypesBiologic useSecondary outcomesMedical therapyPrimary outcomeClinical outcomesMulticenter studyRetrospective studyVedolizumabPatientsCommon typeDiscontinuationArthritis
2012
Relationship Between Proximal Crohn's Disease Location and Disease Behavior and Surgery: A Cross-Sectional Study of the IBD Genetics Consortium
Lazarev M, Huang C, Bitton A, Cho JH, Duerr RH, McGovern DP, Proctor DD, Regueiro M, Rioux JD, Schumm PP, Taylor KD, Silverberg MS, Steinhart AH, Hutfless S, Brant SR. Relationship Between Proximal Crohn's Disease Location and Disease Behavior and Surgery: A Cross-Sectional Study of the IBD Genetics Consortium. The American Journal Of Gastroenterology 2012, 108: 106. PMID: 23229423, PMCID: PMC4059598, DOI: 10.1038/ajg.2012.389.Peer-Reviewed Original ResearchConceptsMultiple abdominal surgeriesCrohn's disease locationAbdominal surgeryDisease locationJejunal diseaseDisease durationStricturing behaviorProximal diseaseIleal diseaseJejunal siteLonger disease durationDiagnosis of CDCross-sectional studyGreatest risk factorSignificant clinical heterogeneityL4 diseaseIleal involvementClinical outcomesDiagnosis ageFirst surgeryMultivariable analysisDisease patientsRisk factorsSurgery riskDisease behavior